Endocrinology, Vol 113, 159-165, Copyright © 1983 by Endocrine Society

ARTICLES

Receptor-mediated mitogenic action of prolactin in a rat lymphoma cell line

RP Shiu, HP Elsholtz, T Tanaka, HG Friesen, PW Gout, CT Beer and RL Noble

PRL and other lactogenic hormones are potent mitogens in a lymphoma cell line derived from a lymph node of an estrogenized Noble (Nb) rat. The present study demonstrates that these cells (designated Nb2 node) possess receptors that bind only lactogenic hormones. There are approximately 12,000 receptor sites per cell. The kinetics of binding of [125I]iodo-PRL exhibited by Nb2 lymphoma cells is unusual in that PRL binding follows a biphasic pattern. Binding of [125I]iodo-PRL reaches a maximum in 1 h at 37 C, followed by a rapid decline. This pattern was not observed if binding was carried out in the presence of chloroquine, a lysosomotropic agent, or if cell homogenate was used for binding. We also examined the relationship between receptor occupancy and the magnitude of PRL response in these cells. Maximal growth stimulation by PRL occurs when only 35% of the maximal binding of PRL is achieved, suggesting that a majority of the PRL binding sites may be spare receptors. This study also revealed that the dissociation constant (Kd) of the PRL receptors in Nb2 cells is 75 pM, approximately 20-fold higher than that of the receptors in other cell types. PRL at 6 pM produces a half-maximal growth response in the Nb2 cells. Antibodies against the PRL receptors are able to abolish the PRL-induced proliferation of Nb2 cells. In the absence of PRL, these antibodies alone can induce proliferation of Nb2 cells, mimicking the action of PRL. Divalent (Fab)2 fragments, but not monovalent Fab, were also effective. These observations suggest that antibodies to the receptor, or the hormone itself, initiate a biological response possibly by cross- linking PRL receptors on the cell membrane, and that the entry of the PRL molecule, or fragments of it, into the intracellular compartment is not necessary for the biological action of PRL.

This article has been cited by other articles:

				E. Biener, C. Martin, N. Daniel, S. J. Frank, V. E. Centonze, B. Herman, J. Djiane, and A. Gertler Ovine Placental Lactogen-Induced Heterodimerization of Ovine Growth Hormone and Prolactin Receptors in Living Cells Is Demonstrated by Fluorescence Resonance Energy Transfer Microscopy and Leads to Prolonged Phosphorylation of Signal Transducer and Activator of Transcription (STAT)1 and STAT3 Endocrinology, August 1, 2003; 144(8): 3532 - 3540. [Abstract] [Full Text] [PDF]

				S. Bernichtein, S. Kinet, S. Jeay, M. Llovera, D. Madern, J. A. Martial, P. A. Kelly, and V. Goffin S179D-Human PRL, a Pseudophosphorylated Human PRL Analog, Is an Agonist and Not an Antagonist Endocrinology, September 1, 2001; 142(9): 3950 - 3963. [Abstract] [Full Text] [PDF]

				A. Ochoa, P. Montes de Oca, J. C. Rivera, Z. Dueñas, G. Nava, G. M. de la Escalera, and C. Clapp Expression of Prolactin Gene and Secretion of Prolactin by Rat Retinal Capillary Endothelial Cells Invest. Ophthalmol. Vis. Sci., June 1, 2001; 42(7): 1639 - 1645. [Abstract] [Full Text]

				F. Behbod, R. A. Erwin-Cohen, M.-E. Wang, B. W. Trawick, X. Qu, R. Verani, B. D. Kahan, S. M. Stepkowski, and R. A. Kirken Concomitant Inhibition of Janus Kinase 3 and Calcineurin-Dependent Signaling Pathways Synergistically Prolongs the Survival of Rat Heart Allografts J. Immunol., March 15, 2001; 166(6): 3724 - 3732. [Abstract] [Full Text] [PDF]

				C. K. L. Too, N. Vickaryous, R. T. M. Boudreau, and S. M. Sangster Identification and Nuclear Localization of a Novel Prolactin and Cytokine-Responsive Carboxypeptidase D Endocrinology, March 1, 2001; 142(3): 1357 - 1367. [Abstract] [Full Text] [PDF]

				M. E. Freeman, B. Kanyicska, A. Lerant, and G. Nagy Prolactin: Structure, Function, and Regulation of Secretion Physiol Rev, October 1, 2000; 80(4): 1523 - 1631. [Abstract] [Full Text] [PDF]

				M. W. Knoferl, M. K. Angele, A. Ayala, W. G. Cioffi, K. I. Bland, and I. H. Chaudry Insight into the mechanism by which metoclopramide improves immune functions after trauma-hemorrhage Am J Physiol Cell Physiol, July 1, 2000; 279(1): C72 - C80. [Abstract] [Full Text] [PDF]

				K. Dorshkind and N. D. Horseman The Roles of Prolactin, Growth Hormone, Insulin-Like Growth Factor-I, and Thyroid Hormones in Lymphocyte Development and Function: Insights from Genetic Models of Hormone and Hormone Receptor Deficiency Endocr. Rev., June 1, 2000; 21(3): 292 - 312. [Abstract] [Full Text]

				R. C. H. Lee, J. A. Walters, M. E. Reyland, and S. M. Anderson Constitutive Activation of the Prolactin Receptor Results in the Induction of Growth Factor-independent Proliferation and Constitutive Activation of Signaling Molecules J. Biol. Chem., April 9, 1999; 274(15): 10024 - 10034. [Abstract] [Full Text] [PDF]

				V. Goffin, S. Kinet, F. Ferrag, N. Binart, J. A. Martial, and P. A. Kelly Antagonistic Properties of Human Prolactin Analogs That Show Paradoxical Agonistic Activity in the Nb2 Bioassay J. Biol. Chem., July 12, 1996; 271(28): 16573 - 16579. [Abstract] [Full Text] [PDF]

				S. Kinet, V. Goffin, V. Mainfroid, and J. A. Martial Characterization of Lactogen Receptor-binding Site 1of Human Prolactin J. Biol. Chem., June 14, 1996; 271(24): 14353 - 14360. [Abstract] [Full Text] [PDF]

				C. Pallard, F. Gouilleux, M. Charon, B. Groner, S. Gisselbrecht, and I. Dusanter-Fourt Interleukin-3, Erythropoietin, and Prolactin Activate a STAT5-like Factor in Lymphoid Cells J. Biol. Chem., July 7, 1995; 270(27): 15942 - 15945. [Abstract] [Full Text] [PDF]